MAIA Biotechnology updates ateganosine program, targeting early commercial approval in NSCLC

MAIA Biotechnology, Inc.

Ateganosine obtained FDA Fast Track designation for NSCLC in 2025; company expects potential Accelerated Approval and Priority Review.
Initiated THIO-104 Phase 3 trial in 3L NSCLC; Phase 2 Part C expansion underway in Asia and Europe.
Awarded $2.3M NIH grant for Phase 2 trial; raised ~$17.6M in 2025 capital raises with board participation.
Targeted 2026 milestones: interim efficacy data from Phase 3, completion of Phase 2 Part C, and start of Phase 1 for second-generation molecules.
Company claims ateganosine is the only telomere-targeting anticancer agent in clinical development globally.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.